{"id":"https://openalex.org/W2060418293","doi":"https://doi.org/10.1097/yic.0000000000000053","title":"Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone","display_name":"Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone","publication_year":2014,"publication_date":"2014-10-30","ids":{"openalex":"https://openalex.org/W2060418293","doi":"https://doi.org/10.1097/yic.0000000000000053","mag":"2060418293","pmid":"https://pubmed.ncbi.nlm.nih.gov/25356632"},"language":"en","primary_location":{"id":"doi:10.1097/yic.0000000000000053","doi":"https://doi.org/10.1097/yic.0000000000000053","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0000000000000053","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045877490","display_name":"Siegfried F. Kasper","orcid":"https://orcid.org/0000-0001-8278-191X","observed_orcids":["https://orcid.org/0000-0001-8278-191X"]},"institutions":[{"id":"https://openalex.org/I2802328216","display_name":"Vienna General Hospital","ror":"https://ror.org/05f0zr486","country_code":"AT","type":"healthcare","lineage":["https://openalex.org/I2802328216"]},{"id":"https://openalex.org/I4210156951","display_name":"Ospedale Versilia","ror":"https://ror.org/05jg53152","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210156951"]},{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT","IT"],"is_corresponding":true,"raw_author_name":"Siegfried Kasper","raw_affiliation_strings":["aDepartment of Psychiatry and Psychotherapy, Medical University, Vienna, Austria bFormer AstraZeneca, Research & Development, Milan cAstraZeneca, Research & Development, Milan dVersilia Hospital, Camaiore, Italy","Department of Psychiatry and Psychotherapy, Medical University, Vienna, Austria","e-mail: [email\u00a0protected]","fax: +43 1 40400 3099","to Siegfried Kasper, MD, PhD, Department of Psychiatry and Psychotherapy, Medical University of Vienna, AKH, W\u00e4hringer G\u00fcrtel 18-20, A-1090 Vienna, Austria Tel: +43 1 40400 3568"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"aDepartment of Psychiatry and Psychotherapy, Medical University, Vienna, Austria bFormer AstraZeneca, Research & Development, Milan cAstraZeneca, Research & Development, Milan dVersilia Hospital, Camaiore, Italy","institution_ids":["https://openalex.org/I4210156951","https://openalex.org/I76134821"]},{"raw_affiliation_string":"Department of Psychiatry and Psychotherapy, Medical University, Vienna, Austria","institution_ids":["https://openalex.org/I76134821"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +43 1 40400 3099","institution_ids":[]},{"raw_affiliation_string":"to Siegfried Kasper, MD, PhD, Department of Psychiatry and Psychotherapy, Medical University of Vienna, AKH, W\u00e4hringer G\u00fcrtel 18-20, A-1090 Vienna, Austria Tel: +43 1 40400 3568","institution_ids":["https://openalex.org/I2802328216","https://openalex.org/I76134821"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088337467","display_name":"Gino Montagnani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gino Montagnani","raw_affiliation_strings":["Former AstraZeneca, Research & Development, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Former AstraZeneca, Research & Development, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055603231","display_name":"Graziella Trespi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Graziella Trespi","raw_affiliation_strings":["AstraZeneca, Research & Development, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Research & Development, Milan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018528526","display_name":"Mario Di Fiorino","orcid":"https://orcid.org/0009-0007-9393-7095","observed_orcids":["https://orcid.org/0009-0007-9393-7095"]},"institutions":[{"id":"https://openalex.org/I4210156951","display_name":"Ospedale Versilia","ror":"https://ror.org/05jg53152","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210156951"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Mario Di Fiorino","raw_affiliation_strings":["Versilia Hospital, Camaiore, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Versilia Hospital, Camaiore, Italy","institution_ids":["https://openalex.org/I4210156951"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5045877490"],"corresponding_institution_ids":["https://openalex.org/I2802328216","https://openalex.org/I4210156951","https://openalex.org/I76134821"],"apc_list":null,"apc_paid":null,"fwci":0.8303,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.70515538,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"30","issue":"1","first_page":"14","last_page":"22"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9319999814033508},{"id":"https://openalex.org/keywords/depressive-symptoms","display_name":"depressive symptoms","score":0.9909999966621399},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antipsychotic-efficacy","display_name":"antipsychotic efficacy","score":0.7210000157356262},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8330000042915344},{"id":"https://openalex.org/keywords/schizoaffective-disorder","display_name":"schizoaffective disorder","score":0.8820000290870667},{"id":"https://openalex.org/keywords/calgary-depression-scale-for-schizophrenia","display_name":"Calgary Depression Scale for Schizophrenia","score":0.9359999895095825},{"id":"https://openalex.org/keywords/hyperprolactinemia","display_name":"hyperprolactinemia","score":0.9240000247955322},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8489999771118164}],"concepts":[{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.8813579082489014},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.8098974227905273},{"id":"https://openalex.org/C2779034229","wikidata":"https://www.wikidata.org/wiki/Q1077823","display_name":"Somnolence","level":3,"score":0.7073172330856323},{"id":"https://openalex.org/C2911140283","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine Fumarate","level":5,"score":0.5409714579582214},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5081958770751953},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.47965458035469055},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4755953252315521},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4634212553501129},{"id":"https://openalex.org/C2780135775","wikidata":"https://www.wikidata.org/wiki/Q7233251","display_name":"Positive and Negative Syndrome Scale","level":3,"score":0.45965877175331116},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.45185911655426025},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4482755661010742},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40532758831977844},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3295503854751587},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.2484438717365265},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.229933500289917},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069348","descriptor_name":"Quetiapine Fumarate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D003987","descriptor_name":"Dibenzothiazepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003987","descriptor_name":"Dibenzothiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007558","descriptor_name":"Italy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012565","descriptor_name":"Schizophrenic Psychology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/yic.0000000000000053","doi":"https://doi.org/10.1097/yic.0000000000000053","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0000000000000053","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:25356632","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25356632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W45776812","https://openalex.org/W1994599653","https://openalex.org/W2019770130","https://openalex.org/W2100233372"],"related_works":["https://openalex.org/W2002876983","https://openalex.org/W2009607401","https://openalex.org/W2371682294","https://openalex.org/W2078957424","https://openalex.org/W2371995684","https://openalex.org/W2581250018","https://openalex.org/W2107642571","https://openalex.org/W2025243014","https://openalex.org/W2081028045","https://openalex.org/W2095450510"],"abstract_inverted_index":{"The":[0,56],"present":[1],"analysis":[2],"assessed":[3],"the":[4],"efficacy":[5],"of":[6,37,59,160],"extended-release":[7],"quetiapine":[8,84,105,130,165],"fumarate":[9],"(quetiapine":[10],"XR)":[11],"versus":[12],"risperidone":[13,90,109,142,163,173],"in":[14,70,95,178],"patients":[15,38,52,82,128,161,179],"with":[16,39,53,180],"schizophrenia":[17,40],"and":[18,27,135,138,148,158,164],"depressive":[19,176],"symptoms":[20,177],"[Hamilton":[21],"Depression":[22,72,97],"Rating":[23],"Scale":[24,73,98],"(HAM-D)":[25],"score\u226520":[26],"a":[28,35,42],"HAM-D":[29],"item":[30],"1":[31],"score\u22652].":[32],"This":[33],"was":[34,63,102,170],"subanalysis":[36],"from":[41,65],"randomized,":[43],"open-label,":[44],"parallel-group,":[45],"flexible-dose":[46],"study":[47,62],"(NCT00640562)":[48],"that":[49],"also":[50],"enrolled":[51],"schizoaffective":[54],"disorder.":[55],"primary":[57],"endpoint":[58],"this":[60],"noninferiority":[61],"change":[64],"baseline":[66],"to":[67,172],"week":[68],"12":[69],"Calgary":[71,96],"for":[74,99,104,108,156],"Schizophrenia":[75,100],"score":[76,101],"(per":[77],"protocol":[78],"population).":[79],"Overall,":[80],"114":[81],"received":[83],"XR":[85,106,131,169],"(n=60;":[86],"400-800":[87],"mg/day)":[88],"or":[89],"(n=54;":[91],"4-6":[92],"mg/day).":[93],"Change":[94],"greater":[103],"than":[107],"[least":[110],"squares":[111],"means:":[112],"-7.2":[113],"vs.":[114],"-4.8;":[115],"treatment":[116],"difference":[117],"2.4":[118],"(95%":[119],"confidence":[120],"interval":[121],"0.3-4.6;":[122],"P<0.05)].":[123],"Adverse":[124],"events":[125],"(\u22653%)":[126],"among":[127,139],"receiving":[129,141,162],"were":[132,143,154],"sedation,":[133],"somnolence,":[134],"dry":[136],"mouth,":[137],"those":[140],"anxiety,":[144],"insomnia,":[145],"asthenia,":[146],"hyperprolactinemia,":[147],"somnolence.":[149],"Abnormally":[150],"high":[151],"prolactin":[152],"levels":[153],"reported":[155],"57.6":[157],"8.1%":[159],"XR,":[166],"respectively.":[167],"Quetiapine":[168],"superior":[171],"at":[174],"reducing":[175],"schizophrenia.":[181]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}